Buy Melanotan II Online
Melanotan II (MT-II) is a synthetic cyclic melanocortin peptide designed as a potent analogue of alpha-melanocyte-stimulating hormone (α-MSH).
It has been researched for melanin production, pigmentation, melanocortin-receptor activity, and sexual-function pathways, making it one of the better-known compounds in melanocortin peptide research.
Product Information
Melanotan II is a cyclic heptapeptide analogue of α-MSH with activity at several melanocortin receptors.
Its strongest recognized biological effect is stimulation of melanogenesis through melanocortin pathways involved in pigmentation. Research has also demonstrated effects on central melanocortin pathways associated with sexual responses.
How Does Melanotan II Work?
Melanotan II activates melanocortin receptors, including MC1R, which stimulates melanin production. Its activity at other melanocortin receptors may also influence central nervous system and sexual function pathways.
Melanotan II Benefits
Stimulates Melanin Production:
Melanotan II was specifically developed to investigate melanocortin-driven pigmentation. In the first human Phase I study, subcutaneous administration produced measurable increases in pigmentation in several participants.
Supports Melanocortin-Receptor Research:
Because MT-II is a potent melanocortin receptor agonist, it provides an important research tool for studying how these receptors influence pigmentation and other physiological processes.
Research Into Sexual-Function Pathways:
The original Phase I study reported spontaneous penile erections following administration, with yawning and stretching appearing to correlate with these responses. These findings helped establish the role of melanocortin signaling in sexual-function research.
Melanotan II Side Effects
The original human Phase I study reported mild nausea, somnolence, fatigue, yawning/stretching, and spontaneous erections. Increased pigmentation was also observed and represents a direct pharmacological effect rather than an unexpected adverse reaction.
Because the original clinical study was very small, consisting of only three male volunteers, it provides limited information about long-term safety.
Melanotan II Dosage
The original Phase I study began with 0.01 mg/kg administered subcutaneously. Two participants were subsequently escalated in 0.005 mg/kg increments to 0.03 mg/kg, while another reached 0.025 mg/kg.
The researchers reported 0.025 mg/kg/day as the recommended single dose for future Phase I studies.
These figures come from a small early-stage clinical study and should be understood as experimental research doses rather than a standardized modern dosing protocol.
Research References
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777–1784. PMID: 8637402.
PubMed — Melanotan II Phase I Clinical Study
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an affiliate-information website and may provide affiliate links to independent third-party suppliers.
The information provided in these pages is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or a recommendation to use any peptide. Research doses are included to describe published study protocols and are not individualized dosing instructions. Product quality, formulation, purity, route of administration, regulatory status, and availability may vary between suppliers and jurisdictions.
